XTX Topco Ltd purchased a new stake in Tempest Therapeutics, Inc. (NASDAQ:TPST – Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor purchased 23,989 shares of the company’s stock, valued at approximately $34,000. XTX Topco Ltd owned approximately 0.10% of Tempest Therapeutics at the end of the most recent quarter.
Other hedge funds also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP acquired a new stake in shares of Tempest Therapeutics in the second quarter valued at about $55,000. Fullcircle Wealth LLC acquired a new stake in Tempest Therapeutics in the third quarter valued at approximately $87,000. Finally, Empower Advisory Group LLC purchased a new stake in shares of Tempest Therapeutics during the third quarter valued at approximately $49,000. 22.52% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $47.00 price target on shares of Tempest Therapeutics in a report on Wednesday, November 13th. Piper Sandler cut their price target on Tempest Therapeutics from $8.00 to $5.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 13th. Finally, William Blair restated an “outperform” rating on shares of Tempest Therapeutics in a research note on Wednesday, November 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Tempest Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $20.00.
Tempest Therapeutics Stock Performance
Shares of Tempest Therapeutics stock opened at $0.71 on Monday. Tempest Therapeutics, Inc. has a 1 year low of $0.70 and a 1 year high of $6.00. The firm’s 50-day simple moving average is $0.95 and its 200-day simple moving average is $1.47. The firm has a market cap of $31.06 million, a PE ratio of -0.47 and a beta of -1.78.
Tempest Therapeutics (NASDAQ:TPST – Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.04). On average, equities analysts predict that Tempest Therapeutics, Inc. will post -1.39 earnings per share for the current year.
About Tempest Therapeutics
Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.
Featured Articles
- Five stocks we like better than Tempest Therapeutics
- What Are the FAANG Stocks and Are They Good Investments?
- XPO Stock Gains Momentum as U.S. Trade Outlook Evolves
- What Are Dividend Champions? How to Invest in the Champions
- CarMax Gets in Gear: Is Now the Time to Buy?
- 5 discounted opportunities for dividend growth investors
- Qubit Combat: 2 Stocks Battle for Quantum Supremacy
Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.